Revenio Group Oyj

Global Ophthalmic Diagnostics Will Expand Through AI Integration

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

16 Jan 25

Updated

27 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-18.4%

7D

-0.7%

Loading

1Y

-18.4%

7D

-0.7%

You can edit this narrative until Nov 28 11:10 PM. Then, changes will post as Updates.

Author's Valuation

€28.7523.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 27 Nov 25

REG1V: Customer-Focused Operating Model Will Drive Long-Term Performance Upside

Analysts have maintained their fair value estimate for Revenio Group Oyj at €28.75, citing only minor adjustments to key assumptions and reaffirming confidence in the company’s long-term outlook. What's in the News Revenio Group Oyj is implementing a new Product Operating Model to increase customer centricity and agility by organizing work, processes, and teams around products (Client Announcements).

Shared on 13 Nov 25

Fair value Decreased 1.54%

REG1V: Modestly Lower Margins and Revenue Will Support Stronger Long-Term Returns

Analysts have lowered their price target for Revenio Group Oyj from €29.20 to €28.75, citing more conservative estimates for revenue growth and profit margins. Valuation Changes The Fair Value Estimate has decreased slightly from €29.20 to €28.75.

Shared on 01 May 25

Fair value Decreased 3.44%

Shared on 23 Apr 25

Fair value Decreased 1.75%

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to 0.0%.

Shared on 17 Apr 25

Fair value Decreased 3.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 1.79%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 2.46%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

€28.75

23.0% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

10.12%

Medical Equipment revenue growth rate

7.91%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.45%

Calculation

€33.70m

Earnings '28

x

26.76x

PE Ratio '28

=

€901.85m

Market Cap '28

€901.85m

Market Cap '28

/

26.57m

No. shares '28

=

€33.95

Share Price '28

€33.95 Share Price '28

Discounted to 2025 @ 6.46% p.a.

=

€28.14

Fair Value '25